Adverse events induced by nivolumab and ipilimumab combination regimens

BACKGROUND: No meta-analysis has assessed the pooled frequencies of adverse events (AEs) induced by concomitant nivolumab plus ipilimumab regimen for anticancer-medications-naïve malignancies. Furthermore, no meta-analysis has compared detailed safety profiles between four doses of nivolumab 3 mg/kg...

Descripción completa

Detalles Bibliográficos
Autores principales: Somekawa, Kohei, Horita, Nobuyuki, Kaneko, Ayami, Tagami, Yoichi, Fukuda, Nobuhiko, Matsumoto, Hiromi, Namkoong, Ho, Fujiwara, Yu, Minegishi, Kaoru, Fukumoto, Takeshi, Watanabe, Keisuke, Hara, Yu, Kobayashi, Nobuaki, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841925/
https://www.ncbi.nlm.nih.gov/pubmed/35173819
http://dx.doi.org/10.1177/17588359211058393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841925/
https://www.ncbi.nlm.nih.gov/pubmed/35173819
http://dx.doi.org/10.1177/17588359211058393

Ejemplares similares